Teneligliptin

Systematic (IUPAC) name
{(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone
Clinical data
Trade names	Tenelia
Legal status	Approved in Japan
Identifiers
CAS Number	760937-92-6
PubChem	CID: 11949652
ChemSpider	10123963
Chemical data
Formula	C22H30N6OS
Molecular mass	426.58 g/mol
SMILES CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5
InChI InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1 Key:WGRQANOPCQRCME-PMACEKPBSA-N

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".

Creation

It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.

Licensing and use

Japan/Korea

It is approved for use in Japan, Korea and India.

Pharmacology

Teneligliptin has unique J shaped or anchor locked domain structure because of which it has more potent inhibition of DPP 4 enzyme as compared to Sitagliptin and Vildagliptin.

Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.